Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Figure 5
(A) Immunostaining of insulin (red), BrdU (yellow), and DAPI (blue) in pancreas sections from BrdU treated non-diabetic control mice and diabetic mice with restored normoglycemia after 7 weeks of treatment with PSN632408, sitagliptin, or PSN632408 combined with sitagliptin.
White arrows indicate insulin/BrdU/DAPI co-positive cells. (B) The percentage of insulin/BrdU co-positive cells among total insulin positive cells was significantly higher in mice treated with PSN632408 and sitagliptin combination than in mice treated with PSN632408 alone (p<0.01, n = 4 to 6 mice per group).